BACKGROUND: A subset of HIV-infected patients, termed 'elite' viral controllers, maintain undetectable plasma HIV RNA levels in the absence of therapy. In this group, host-mediated viral control may be accompanied by chronic systemic inflammation. It is unknown whether either infection or chronic inflammation is present within the central nervous system of these individuals. METHODS: Cross-sectional analysis compared cerebrospinal fluid (CSF) HIV RNA and biomarkers of intrathecal inflammation in eight controllers (plasma HIV RNA levels <50 copies/ml) with 26 HIV-uninfected individuals, 25 untreated individuals HIV-infected, viremic individuals, and 23 HIV-infected individuals with treatment-mediated viral suppression (plasma HIV RNA levels <50 copies/ml). RESULTS: All controllers had CSF HIV RNA levels below 2.5 copies/ml. CSF white blood cell (WBC) counts and CSF: plasma albumin ratios in the controllers were similar to those in both HIV-uninfected individuals and antiretroviral therapy-suppressed HIV-infected individuals. CSF neopterin, MCP-1, and IP-10 concentrations were also not different in the controllers from either HIV-uninfected or treated HIV-infected individuals. CONCLUSION: The character of CSF HIV infection and degree of immunoactivation in controllers is comparable to that of HIV-uninfected and antiretroviral therapy-suppressed HIV-infected individuals, but distinct from that of untreated, viremic HIV-infected individuals.
BACKGROUND: A subset of HIV-infectedpatients, termed 'elite' viral controllers, maintain undetectable plasma HIV RNA levels in the absence of therapy. In this group, host-mediated viral control may be accompanied by chronic systemic inflammation. It is unknown whether either infection or chronic inflammation is present within the central nervous system of these individuals. METHODS: Cross-sectional analysis compared cerebrospinal fluid (CSF) HIV RNA and biomarkers of intrathecal inflammation in eight controllers (plasma HIV RNA levels <50 copies/ml) with 26 HIV-uninfected individuals, 25 untreated individuals HIV-infected, viremic individuals, and 23 HIV-infected individuals with treatment-mediated viral suppression (plasma HIV RNA levels <50 copies/ml). RESULTS: All controllers had CSF HIV RNA levels below 2.5 copies/ml. CSF white blood cell (WBC) counts and CSF: plasma albumin ratios in the controllers were similar to those in both HIV-uninfected individuals and antiretroviral therapy-suppressed HIV-infected individuals. CSF neopterin, MCP-1, and IP-10 concentrations were also not different in the controllers from either HIV-uninfected or treated HIV-infected individuals. CONCLUSION: The character of CSF HIV infection and degree of immunoactivation in controllers is comparable to that of HIV-uninfected and antiretroviral therapy-suppressed HIV-infected individuals, but distinct from that of untreated, viremic HIV-infected individuals.
Authors: Viktor Dahl; Julia Peterson; Serena Spudich; Evelyn Lee; Barbara L Shacklett; Richard W Price; Sarah Palmer Journal: AIDS Date: 2013-04-24 Impact factor: 4.177
Authors: Lishomwa C Ndhlovu; Michelle L D'Antoni; Jintanat Ananworanich; Mary Margaret Byron; Thep Chalermchai; Pasiri Sithinamsuwan; Somporn Tipsuk; Erika Ho; Bonnie M Slike; Alexandra Schuetz; Guangxiang Zhang; Melissa Agsalda-Garcia; Bruce Shiramizu; Cecilia M Shikuma; Victor Valcour Journal: J Neuroimmunol Date: 2015-09-04 Impact factor: 3.478
Authors: Magnus Gisslen; Sheila M Keating; Serena Spudich; Victor Arechiga; Sophie Stephenson; Henrik Zetterberg; Clara Di Germanio; Kaj Blennow; Dietmar Fuchs; Lars Hagberg; Philip J Norris; Julia Peterson; Barbara L Shacklett; Constantin T Yiannoutsos; Richard W Price Journal: PLoS One Date: 2021-05-13 Impact factor: 3.240
Authors: Thomas E Angel; Jon M Jacobs; Serena S Spudich; Marina A Gritsenko; Dietmar Fuchs; Teri Liegler; Henrik Zetterberg; David G Camp; Richard W Price; Richard D Smith Journal: Clin Proteomics Date: 2012-03-20 Impact factor: 3.988
Authors: Julia Peterson; Magnus Gisslen; Henrik Zetterberg; Dietmar Fuchs; Barbara L Shacklett; Lars Hagberg; Constantin T Yiannoutsos; Serena S Spudich; Richard W Price Journal: PLoS One Date: 2014-12-26 Impact factor: 3.240
Authors: Anupama Ganesh; Donna Lemongello; Evelyn Lee; Julia Peterson; Bridget E McLaughlin; April L Ferre; Geraldine M Gillespie; Dietmar Fuchs; Steven G Deeks; Peter W Hunt; Richard W Price; Serena S Spudich; Barbara L Shacklett Journal: AIDS Res Hum Retroviruses Date: 2016-05-02 Impact factor: 2.205
Authors: Sam Nightingale; Benedict D Michael; Martin Fisher; Alan Winston; Mark Nelson; Steven Taylor; Andrew Ustianowski; Jonathan Ainsworth; Richard Gilson; Lewis Haddow; Edmund Ong; Clifford Leen; Jane Minton; Frank Post; Apostolos Beloukas; Ray Borrow; Munir Pirmohamed; Anna Maria Geretti; Saye Khoo; Tom Solomon Journal: Cytokine Date: 2016-04-28 Impact factor: 3.861
Authors: Timothy J Henrich; Hiroyu Hatano; Oliver Bacon; Louise E Hogan; Rachel Rutishauser; Alison Hill; Mary F Kearney; Elizabeth M Anderson; Susan P Buchbinder; Stephanie E Cohen; Mohamed Abdel-Mohsen; Christopher W Pohlmeyer; Remi Fromentin; Rebecca Hoh; Albert Y Liu; Joseph M McCune; Jonathan Spindler; Kelly Metcalf-Pate; Kristen S Hobbs; Cassandra Thanh; Erica A Gibson; Daniel R Kuritzkes; Robert F Siliciano; Richard W Price; Douglas D Richman; Nicolas Chomont; Janet D Siliciano; John W Mellors; Steven A Yukl; Joel N Blankson; Teri Liegler; Steven G Deeks Journal: PLoS Med Date: 2017-11-07 Impact factor: 11.069